Researchers may have come up with a new treatment for serious skin infections like MRSA.
Scientists at Duke University say in a 3-year study, a single, intravenous infusion of the drug Oritavancin was just as effective in treating resistant infections as the current standard drug, Vancomycin, which is taken twice a day for up to ten days.
Researchers say a key advantage to the new drug is that it can stay in the body for a longer period of time. The study author says, “you can be discharged from the ER to go back home and gradually cure the infection over the next 7 to 10 days.
The drug maker funded the study and has submitted the results to the FDA. Researchers say there were minor side effects, including nausea and headaches.
Agencies/Canadajournal
Canada Journal – News of the World Articles and videos to bring you the biggest Canadian news stories from across the country every day
